Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 1.00 |
| ▸ | KIT | P10721 | 13/20 | 1.00 |
| ▸ | BCR | P11274 | 12/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.84 |
| ▸ | ABL2 | P42684 | 4/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | DDX3X | O00571 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.84 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | CA1 | P00915 | 1/20 | 0.84 |
| ▸ | CA2 | P00918 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | ALB | P02768 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410182 | 1.00 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4405514 | 0.97 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3064834 | 0.95 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3264382 | 0.95 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL31553098 | 0.95 | ABL1 (0.94) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL19586397 | 0.94 | ABL1 (0.89) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4394539 | 0.93 | ABL1 (0.88) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3058299 | 0.93 | ABL1 (0.86) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL12127861 | 0.92 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4399517 | 0.92 | ABL1 (0.87) | ABL1KITBCRLRRK2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| US-20170007605-A1 | Method of Optimizing the Treatment of Philadelphia-positive Leukemia with Abl Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2017-01-12 | — | — | US | claimed |
| WO-2011095835-A1 | HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-11 | — | — | WO | claimed |
| EP-2251042-A2 | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors | Novartis AG (CH) | 2010-11-17 | — | — | EP | claimed |
| EP-1322634-B1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-16 | — | — | EP | claimed |
| US-20090281113-A1 | METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-12 | — | — | US | claimed |
| EP-2068938-A2 | METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| US-20080214445-A1 | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | claimed |
| EP-1951243-A2 | TREATMENT OF SOLID TUMOR DISEASE WITH COMBINATIONS COMPRISING IMATINIB AND AN EFFLUX PUMP INHIBITOR | Novartis AG (CH) | 2008-08-06 | — | — | EP | claimed |
| WO-2008036792-A2 | METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| WO-2006136391-A2 | TREATMENT OF SOLID TUMOR DISEASE WITH COMBINATIONS COMPRISING IMATINIB AND AN EFFLUX PUMP INHIBITOR | NOVARTIS AG (CH) | 2006-12-28 | — | — | WO | claimed |
| US-7081532-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2006-07-25 | — | — | US | claimed |
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2004-05-27 | — | — | US | claimed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | claimed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
| CN-119816297-A | Parenteral formulation of imatinib | 阿尔托润吉有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NUDT1, PNP, TYMP | ABL1 68/4885KIT 352/4885BCR 4165/4885 |
| US-20170007605-A1 | Method of Optimizing the Treatment of Philadelphia-positive Leukemia with Abl Tyrosine Kinase Inhibitors | ABL1, BCR, MPL | ABL1 1/4885KIT 73/4885BCR 2/4885 |
| US-20090281113-A1 | METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS | ABL1, BCR, MPL | ABL1 1/4885KIT 77/4885BCR 2/4885 |
| US-20080214445-A1 | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib | ABL1, TPMT, ABCB1 | ABL1 1/4885KIT 149/4885BCR 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.